Healthcare / Drug Manufacturers - Specialty & GenericNYSE American
$0.77
-0.02 (-2.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-697781.00 · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$31M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.0%
↓Gross Margin
-3.2%
↓Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
-17.5%
FCF CAGR
-35.5%
FCF margin
0.3%
FCF / Net income
-0.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.1M · net income $-3.2M · FCF $11010.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $4.1M | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M | $10.9M | $12.3M | $13.2M | $15.6M | $20.4M | $22.1M | $32.8M | $54.5M | $81.2M | $74.4M |
| Net Income | $-3.2M | $-3.2M | $-4.7M | $-3.1M | $-4.0M | $-3.4M | $-2.9M | $-20.7M | $-10.8M | $-19.3M | $-9.2M | $-15.4M | $-39.6M | $-20.0M | $4.6M | $19.3M | $23.4M |
| EBITDA | $-1.5M | $-1.5M | $-1.9M | $8435.00 | $-837689.00 | $227310.00 | $101177.00 | $-17.5M | $-7.2M | $-15.4M | $-5.1M | $-10.7M | $-37.0M | $-17.0M | $7.4M | $23.2M | $26.2M |
| EPS | -7.40 | -7.40 | -2.71 | -9.10 | -37.80 | -37.00 | — | — | — | — | — | -175.00 | -455.00 | -230.00 | 55.00 | 220.00 | 270.00 |
| Gross Margin | -3.2% | -3.2% | -43.8% | -4.0% | -6.1% | 3.6% | 18.0% | 13.6% | 16.0% | 18.7% | 20.7% | 7.2% | 12.1% | -1.5% | 25.8% | 35.7% | 40.7% |
| Operating Margin | -74.5% | -74.5% | -101.2% | -39.5% | -45.0% | -29.7% | -23.7% | -186.8% | -84.7% | -141.4% | -52.4% | -70.3% | -175.1% | -56.7% | 10.8% | 27.1% | 33.2% |
| Net Margin | -76.9% | -76.9% | -104.6% | -43.9% | -49.0% | -35.3% | -26.4% | -189.5% | -87.2% | -145.9% | -59.0% | -75.7% | -178.7% | -61.0% | 8.5% | 23.7% | 31.5% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.17 | 0.17 | 0.48 | 0.62 | 2.04 | — | 0.65 | 0.47 | 0.22 | 0.21 | — | — | — | — | — | — | — |
| Current Ratio | 0.32 | 0.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $11010.00 | $11010.00 | $-697781.00 | $-711203.00 | $-811509.00 | $-687893.00 | $-909567.00 | $472309.00 | $1.8M | $704737.00 | $2.7M | $4.0M | $1.0M | $27.4M | $3.8M | $5.6M | $7.8M |
| Returns | |||||||||||||||||
| ROE | -14.0% | -14.0% | -61.1% | -41.3% | -92.6% | -56.5% | -35.8% | -224.1% | -35.6% | -44.8% | -15.6% | -21.2% | -42.6% | -15.0% | 3.1% | 13.5% | 19.9% |
| Valuation | |||||||||||||||||
| EV/EBITDA | — | — | — | 581.15 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.01 | 0.01 | 0.52 | 0.23 | 1.23 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | -8.5% | -8.5% | -35.4% | -13.5% | — | -11.3% | -0.5% | -11.4% | -6.7% | -15.1% | -23.5% | -8.1% | -32.5% | -39.8% | -32.8% | 9.1% | — |
| EPS Growth | -173.1% | -173.1% | 70.2% | 75.9% | — | — | — | — | — | — | — | 61.5% | -97.8% | -518.2% | -75.0% | -18.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.71 → -7.40
Residual
-51.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.